Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Meropenem
Drug ID BADD_D01393
Description Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death. In August 2017, a combination antibacterial therapy under the market name vabomere was approved for treatment of adult patients with complicated urinary tract infections (cUTI). Vabomere consists of meropenem and [DB12107] and is intravenously admininstered. The treatment aims to resolve infection-related symptoms and achieve negative urine culture, where the infections are proven or strongly suspected to be caused by susceptible bacteria.
Indications and Usage For use as single agent therapy for the treatment of the following infections when caused by susceptible isolates of the designated microorganisms: complicated skin and skin structure infections due to Staphylococcus aureus (b-lactamase and non-b-lactamase producing, methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (excluding vancomycin-resistant isolates), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis and Peptostreptococcus species; complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. Also for use in the treatment of bacterial meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (b-lactamase and non-b-lactamase-producing isolates), and Neisseria meningitidis.
Marketing Status Prescription; Discontinued
ATC Code J01DH02
DrugBank ID DB00760
KEGG ID D02222
MeSH ID D000077731
PubChem ID 441130
TTD Drug ID D0O5FY
NDC Product Code 44567-146; 38217-0021; 70594-075; 72572-415; 70121-1453; 44567-401; 0781-3000; 70278-104; 0409-1390; 63323-508; 63323-507; 70594-076; 70121-1454; 70278-103; 0409-1391; 68083-146; 55150-208; 72572-416; 44647-032; 44567-145; 0781-3098; 52946-0839; 44567-400; 44647-033; 55150-207; 68001-324; 0069-0314; 38217-0020; 68083-147; 68001-447; 68001-323; 68001-446
Synonyms Meropenem | 3-(5-Dimethylcarbamoylpyrrolidin-3-ylthio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid | Merrem | Ronem | Penem | SM 7338 | SM-7338 | SM7338
Chemical Information
Molecular Formula C17H25N3O5S
CAS Registry Number 96036-03-2
SMILES CC1C2C(C(=O)N2C(=C1SC3CC(NC3)C(=O)N(C)C)C(=O)O)C(C)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Enterococcal infection11.02.08.0020.000213%Not Available
Infestation23.09.05.001; 11.09.01.001--Not Available
Inflammation08.01.05.007--Not Available
Lung infection22.07.01.008; 11.01.09.0080.000056%
Partial seizures17.12.03.0100.000319%Not Available
Decreased appetite08.01.09.028; 14.03.01.005--
Pseudomonas infection11.02.12.0010.000213%Not Available
Urinary tract obstruction20.08.01.0040.000213%
Blood disorder01.05.01.004--Not Available
Disease progression08.01.03.038--
Hepatobiliary disease09.01.08.003--Not Available
Renal impairment20.01.03.0100.001384%Not Available
Hyperamylasaemia14.11.01.0030.000213%Not Available
Vulvovaginal mycotic infection21.14.02.004; 11.03.05.004--Not Available
Bone marrow failure01.03.03.0050.000417%
Treatment failure08.06.01.0170.000056%Not Available
Hypertransaminasaemia09.01.02.0050.000319%Not Available
Acute kidney injury20.01.03.0160.001703%
Drug-induced liver injury12.03.01.044; 09.01.07.0230.000426%Not Available
Drug reaction with eosinophilia and systemic symptoms23.03.05.005; 10.01.01.0210.001916%Not Available
Pneumocystis jirovecii pneumonia22.07.08.009; 11.03.07.0050.000056%Not Available
Candida infection11.03.03.0210.000194%
Body temperature abnormal13.15.01.0300.000213%Not Available
Activated partial thromboplastin time ratio fluctuation13.01.02.034--Not Available
Multiple organ dysfunction syndrome08.01.03.0570.000250%
Convulsive threshold lowered17.12.03.0230.000532%Not Available
Dermatitis exfoliative generalised10.01.01.029; 23.03.07.0020.000213%Not Available
Nosocomial infection11.07.02.0060.000111%Not Available
Respiratory rate increased13.15.01.0040.000213%Not Available
Acinetobacter infection11.02.01.0330.000213%Not Available
The 10th Page    First    Pre   10 11    Next   Last    Total 11 Pages